Bristol-Myers Squibb's Q4 Earnings Update Shows Why It Needs Celgene

Bristol-Myers Squibb (NYSE: BMY) reported very good fourth-quarter results on Thursday. Revenue jumped 10% year over year, with strong growth for blockbuster drugs Opdivo and Eliquis leading the way. The drugmaker easily beat Wall Street earnings estimates, posting adjusted earnings per share of $0.94 compared to the consensus analysts' estimate of $0.85.